WELICEF 500 contains Ceftriaxone 500 mg in an injectable dosage form for selected susceptible bacterial infections requiring parenteral therapy. Its established cephalosporin profile, broad clinical utility and convenient hospital presentation provide strong positioning across physician-led and institutional treatment settings. It is a dependable building block for a comprehensive PCD Pharma Injectable Antibiotic range, particularly where lower-strength Ceftriaxone presentations are clinically appropriate.
Selected susceptible bacterial infections requiring injectable therapy.
No.
It offers broad activity, convenient parenteral administration and a prolonged duration that can support practical dosing schedules in appropriate patients.
Administration should be performed by qualified healthcare professionals. Review allergy history and the suspected site and severity of infection before treatment. Follow microbiological and institutional antibiotic guidance where available. Monitor clinical response and adverse effects, and adjust treatment when culture information or clinical response indicates a different approach.
Commonly reported effects include diarrhea, nausea, vomiting, abdominal discomfort, headache, rash and injection-site discomfort. Allergic reactions may occur, particularly in individuals with previous beta-lactam hypersensitivity. Laboratory abnormalities affecting liver function may occasionally occur. Rare serious reactions require urgent care. Patients should be monitored for severe rash, breathing difficulty, facial swelling, persistent diarrhea or unexplained deterioration during antibiotic treatment.
WELICEF 500: Ceftriaxone acts by binding to bacterial penicillin-binding proteins and blocking bacterial cell-wall synthesis. By interfering with peptidoglycan formation, it compromises the structural integrity of susceptible bacteria and causes cell death. Its broad antibacterial spectrum and relatively prolonged duration of action make it suitable for selected infections requiring parenteral therapy. The injectable formulation provides reliable administration in hospital and supervised clinical environments.
